Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × INDUSTRY × Adrenal Insufficiency × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 431 Neoplasms 310 Breast Neoplasms 300 Colorectal Neoplasms 243 Neoplasm Metastasis 191 Ovarian Neoplasms 172 Lung Neoplasms 159 Recurrence 153 Prostatic Neoplasms 146 Pancreatic Neoplasms 141 Squamous Cell Carcinoma of Head and Neck 133 Multiple Myeloma 133 Stomach Neoplasms 125 Melanoma 122 Endometrial Neoplasms 119 Leukemia, Myeloid, Acute 118 Advanced Solid Tumor 116 Advanced Solid Tumors 105 Triple Negative Breast Neoplasms 103 Carcinoma, Hepatocellular 101 Uterine Cervical Neoplasms 91 Small Cell Lung Carcinoma 85 Lymphoma, Non-Hodgkin 82 Lymphoma 73 Carcinoma, Renal Cell 69 Solid Tumor 67 Lymphoma, Follicular 66 Lymphoma, Large B-Cell, Diffuse 65 Leukemia, Lymphocytic, Chronic, B-Cell 64 Urinary Bladder Neoplasms 60

Interventions

ravulizumab 1 Prednisone 1 Prednisolone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡